Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.79 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.66 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.66 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | SRC | P12931 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8006768 | 0.88 | FGFR1 (1.00) | KDRFGFR1HTTALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL7989899 | 0.87 | FGFR1 (0.97) | KDRFGFR1HTTALDH1A1HPGD | |
| SCHEMBL12135624 | 0.87 | KDR (0.76) | KDRFGFR1HTTALDH1A1SRC | |
| SCHEMBL2644889 | 0.86 | FGFR1 (0.80) | KDRFGFR1HTTALDH1A1HPGD | |
| SCHEMBL18609552 | 0.85 | KDR (0.74) | KDRFGFR1HTTALDH1A1HPGD | |
| SCHEMBL769342 | 0.83 | KDR (0.70) | KDRFGFR1HTTALDH1A1HPGD | |
| SCHEMBL1408358 | 0.82 | KDR (0.69) | KDRFGFR1HTTALDH1A1HPGD | |
| SCHEMBL19781279 | 0.81 | KDR (0.68) | KDRFGFR1HTTALDH1A1HPGD | |
| SCHEMBL7677283 | 0.81 | KDR (0.68) | KDRFGFR1HTTALDH1A1HPGD | |
| SCHEMBL7676755 | 0.81 | GAK (0.73) | KDRFGFR1HTTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109555-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | claimed |
| EP-1109555-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2001-06-27 | — | — | EP | claimed |
| US-6162804-A | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2000-12-19 | — | — | US | claimed |
| EP-1017682-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2000-11-08 | — | — | EP | claimed |
| EP-1017682-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2000-07-12 | — | — | EP | claimed |
| WO-2000012089-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 2000-03-09 | — | — | WO | claimed |
| WO-1999016755-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 1999-04-08 | — | — | WO | claimed |
| US-6465484-B1 | TYROSINE KINASE INHIBITORS; CANCER, ATHEROSCLEROSIS, DIABETIC RETINOPATHY, AUTOIMMUNE DISEASES, INFLAMMATORY DISEASES | MERCK & CO., INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1109555-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1109555-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6162804-A | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2000-12-19 | — | — | US | disclosed |
| EP-1017682-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1017682-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-2000012089-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999016755-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 1999-04-08 | — | — | WO | disclosed |